Bicycle Therapeutics vs Foghorn Therapeutics
BCYC and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCYC and FHTX compare
Bicycle Therapeutics is the larger company, worth 1.9 times as much as Foghorn Therapeutics ($236M against $123M).
Foghorn Therapeutics grew revenue faster over the last twelve months (357% versus 195% for Bicycle Therapeutics).
Foghorn Therapeutics keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −170% at Bicycle Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCYC | FHTX |
|---|---|---|
| Size and price | ||
| Market cap | $236M | $123M |
| Share price | $3.37 | $2.07 |
| Change, 1 year | −48.6% | −54.3% |
| Change, 5 years | −94.2% | −84.9% |
| Beta (5Y) | 1.37 | 1.87 |
| Employees | 288 | 106 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 3 (better) | 2 |
| Growth score | 2 | 2 |
| Performance score | 2 | 2 |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 29.6× |
| P/S | 2.8× | 1.1× (better) |
| P/B | 0.5× | – |
| EV/EBITDA | – | 11.1× |
| FCF yield | −74.9% | −68.1% (better) |
| Fair value | $16.02 | $2.09 |
| Margin of safety | 79.0% (better) | 0.79% |
| Growth | ||
| Revenue growth (TTM) | 195% | 357% (better) |
| Revenue growth, 5Y average | 47.5% | 135% (better) |
| Profitability | ||
| Operating margin | −189% | 2.1% (better) |
| Net margin | −170% | 8.4% (better) |
| FCF margin | −212% | −74.6% (better) |
| Return on equity | −25.2% | – |
| Return on invested capital | −4543% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | −815.6× | – |
| Current ratio | 12.09 (better) | 4.24 |
| Altman Z-score | 0.04 (better) | −2.66 |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 53.4% | 75.6% |
| Held by insiders | 21.3% | 36.3% |
| Insider net buying, 12 months | −$523K | – |
| Short interest, % of float | – | 6.0% |
Go deeper
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
- FHTX stock overview
- FHTX income statement
- FHTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.